DNAnexus raises $100M for a cloud-based analytics platform aimed at genomics and other clinical big data – TipsClear

DNAnexus, which provides a cloud platform for governments, universities, doctors and pharmaceutical companies to tap into DNA and other clinical datasets and collaborate on scientific research projects, is today a major effort in expanding its reach and purpose. Is taking the step forward. The 10-year-old startup, originally outfitted with Stanford School of Medicine, has raised $ 100 million in funding.

Gol, technically a series G, is being co-led by Perceptive Advisors and Northpond Ventures (both specialist science and biotech investors), with past backers GV (which has been around since the beginning), Forcite Capital, TPG Is with the participation of. Capital, and the capital of the first round. DNAnexus is also taking a new strategic base in this era: Regeneron Pharmaceuticals – currently one of several companies working on antibody therapy for COVID-19 recovery.

Indeed, the idea would be to use the funds to continue building that platform and use cases around it, especially as research around the current coronovirus global health epidemic has boomed.

“This financing accelerates the advancement of our data science technologies benefiting our rapidly growing customer base,” DNANexus CEO Richard Daly said in a statement. “The next wave of biomedical insights and treatments will be driven largely by clinical, multi-omics, and real-world data, generated by cross-institutional collaboration. Our customers continue to evolve during the current COVID-19 epidemic using the virtual cloud workspace we provide. The trend towards cloud-based data analysis and collaboration is accelerating, and we are in the right place at the right time to proof and serve our customers in the future. “

The funding is the largest round raised by DNANexus, which had previously raised about $ 127 million with other investors, including Microsoft and Felicis, according to PitchBook data. It is not disclosing an assessment but we are asking.

As some of the markers of where it sits as a business, however, a spokesperson says the platform is used by eight of the top 10 clinical diagnostics companies and seven of the world’s largest pharmaceutical companies , Which use 10 million core processing hours each month and in store, 28 petabytes of data, a figure that has grown 70% annually over the past four years.

It also included some very notable partners. They include the UK Biobank – an academic-run data trove based on genomic and clinical data from some 500,000 volunteer participants, for which DNANexus provides an interface to query data more easily. And it is working with government groups such as the Food and Drug Administration, it uses to help run a database that works with other organizations, and genomic variation, an essential component of DNA-based medical research Helps track.

It is a rocky road to DNA and how it has been viewed by consumers in recent years. Once conducted as a sort of Rosetta Stone, we have never been able to answer those questions about the way our bodies work, where we come from, and who exactly did it. For example, companies that offer DNA data to average people have recently had a spotlight on ethics and data privacy questions. As a business, it also sounds like some of the leading names in the space have found interest in the field.

DNAnexus sits adjacent, but is quite different from those streams. The company certainly got its start around the time when others like 23andme were popularizing the idea of ​​democratizing DNA information, but its roots have always been in the greater arcane, but serious aspects of the DNA business and its challenges. There are also: better how-to’s and queries that are essentially very large and untested datasets to spark actionable insights.

It is more than just about DNA, working with other large and often unstructured clinical datasets to help others in the field use the data more wisely and with the right privacy compliance in place (which makes the data ” Is another type of “intelligent”), part of a larger tendency to develop drugs that are more associated with individuals rather than one-size-fits-all solutions that often miss the mark, especially complex deformities. In, such as cancer care. Tapping into AI to manufacture medicine, it is one of the more cutting-edge, but still attractive, fields in medicine today.

“The precision medicine market is poised to exceed $ 119 billion by 2026. Many pharmaceutical companies and medical centers are adopting strategies rooted in human genetics as evidence suggests that the clinical success of a drug when associated with a specific biomarker Doubles the likelihood of, “said Michael Rubin, MD, PhD, The founder and CEO of Northpond Ventures, in a statement. “Providing the ecosystem with a tool to analyze and gain insights from all these large datasets is a difficult undertaking. DNANexus has a proven product that scales. “

Related Posts